Rationale for using centralized transduction inhibition assays in three phase 3 rAAV gene therapy clinical trials
Mol Ther Methods Clin Dev
.
2023 Oct 11:31:101119.
doi: 10.1016/j.omtm.2023.101119.
eCollection 2023 Dec 14.
Authors
Martin Schulz
1
,
George Bashirians
1
,
Seng H Cheng
1
,
Daniel I Levy
1
,
Mark Lundie
1
,
Lisa Wilcox
1
,
Ian Winburn
1
,
Suryanarayan Somanathan
1
Affiliation
1
Pfizer, 235 East 42 Street, New York, NY 10017, USA.
PMID:
37868207
PMCID:
PMC10585313
DOI:
10.1016/j.omtm.2023.101119
No abstract available
Publication types
Editorial